litlas
Log inCreate account

David Raben

Active 1978–2025

65
Papers
19,162
Citations
55
h-index
63
i10-index

Citations

Citations per year for David Raben1980: 4 citations1981: 2 citations1983: 1 citations1985: 2 citations1987: 1 citations1994: 4 citations1995: 5 citations1996: 2 citations1997: 1 citations1998: 1 citations1999: 13 citations2000: 16 citations2001: 13 citations2002: 18 citations2003: 26 citations2004: 33 citations2005: 47 citations2006: 63 citations2007: 103 citations2008: 114 citations2009: 110 citations2010: 160 citations2011: 127 citations2012: 125 citations2013: 129 citations2014: 145 citations2015: 134 citations2016: 147 citations2017: 158 citations2018: 115 citations2019: 697 citations2020: 641 citations2021: 585 citations2022: 439 citations2023: 346 citations2024: 479 citations2025: 218 citations2026: 8 citations1982: no citations, so this year is not shown1984: no citations, so this year is not shown1986: no citations, so this year is not shown1988–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,096 citing papers, 29.2% of this breakdownChina: 831 citing papers, 11.6% of this breakdownGermany: 371 citing papers, 5.2% of this breakdownUnited Kingdom: 346 citing papers, 4.8% of this breakdownItaly: 312 citing papers, 4.3% of this breakdownFrance: 305 citing papers, 4.2% of this breakdownCanada: 258 citing papers, 3.6% of this breakdownNetherlands: 239 citing papers, 3.3% of this breakdownJapan: 218 citing papers, 3% of this breakdownSpain: 177 citing papers, 2.5% of this breakdownAustralia: 158 citing papers, 2.2% of this breakdownSouth Korea: 137 citing papers, 1.9% of this breakdown
0%29.2%Other 24.2%

Institutions

Fields

  • Medicine67.5%
  • Biochemistry, Genetics and Molecular Biology22.3%
  • Immunology and Microbiology4.3%
  • Engineering1.2%
  • Physics and Astronomy0.9%
  • Neuroscience0.7%
  • Other3.1%

Topics

  • Head and Neck Cancer Studies9.9%
  • Cancer Immunotherapy and Biomarkers4.4%
  • Lung Cancer Treatments and Mutations3.8%
  • Esophageal Cancer Research and Treatment2.3%
  • Head and Neck Surgical Oncology2%
  • HER2/EGFR in Cancer Research1.9%
  • Other75.7%

Coauthors

All papers

Open in search
  1. Head and neck cancer

    Authors: Athanassios Argiris, Michalis V. Karamouzis, David Raben, Robert L. Ferris - The Lancet 2008 cited by 2,220

  2. Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

    Authors: James A. Bonner, Paul M. Harari, J. Giralt, N. Azarnia, Dong M. Shin, Roger B. Cohen, Christopher U. Jones, Ranjan Sur, David Raben, Jacek Jassem, Roger Ove, Merrill S. Kies, José Baselga, Hagop Youssoufian, Nadia Amellal, Eric K. Rowinsky, K. Kian Ang - New England Journal of Medicine 2006 cited by 5,106

  3. Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapy

    Authors: Qian Huang, Fang Li, Xinjian Liu, Wenrong Li, Wei Shi, Fei‐Fei Liu, Brian O’Sullivan, Zhimin He, Yuanlin Peng, Aik Choon Tan, Ling Zhou, Jingping Shen, Gangwen Han, Xiao‐Jing Wang, Jackie Thorburn, Andrew Thorburn, Antonio Jimeno, David Raben, Joel S. Bedford, Chuan‐Yuan Li - Nature Medicine 2011 cited by 896

  4. A phase I/Ib trial and biological correlate analysis of neoadjuvant SBRT with single-dose durvalumab in HPV-unrelated locally advanced HNSCC

    Authors: Laurel B. Darragh, Michael W. Knitz, Junxiao Hu, Eric T. Clambey, Jennifer Backus, Andrew Dumit, Von Samedi, Andrew N. Bubak, Casey S. Greene, Timothy V. Waxweiler, Sanjana Mehrotra, Shilpa Bhatia, Jacob Gadwa, Thomas E. Bickett, Miles Piper, Kareem Fakhoury, Arthur Liu, Joshua H. Petit, Daniel W. Bowles, Ashesh A. Thaker, Kimberly Atiyeh, Julie Goddard, Robert Hoyer, Adrie van Bokhoven, Kimberly R. Jordan, Antonio Jimeno, Angelo D’Alessandro, David Raben, Jessica D. McDermott, Sana D. Karam - Nature Cancer 2022 cited by 91

  5. Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration

    Authors: Ayman Oweida, Mohammad K. Hararah, Andy V. Phan, David C. Binder, Shilpa Bhatia, Shelby Lennon, Sanjana Bukkapatnam, Benjamin Van Court, Nomin Uyanga, Laurel B. Darragh, H. Mike Kim, David Raben, Aik Choon Tan, Lynn E. Heasley, Eric T. Clambey, Raphael A. Nemenoff, Sana D. Karam - Clinical Cancer Research 2018 cited by 279

  6. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival

    Authors: James A. Bonner, Paul M. Harari, J. Giralt, Roger B. Cohen, Christopher U. Jones, Ranjan Sur, David Raben, José Baselga, Sharon A. Spencer, Junming Zhu, Hagop Youssoufian, Eric K. Rowinsky, K. Kian Ang - The Lancet Oncology 2009 cited by 1,974

  7. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study

    Authors: Brian O’Sullivan, Shao Hui Huang, Jie Su, Adam S. Garden, Erich M. Sturgis, Kristina R. Dahlstrom, Nancy Y. Lee, Nadeem Riaz, Xin Pei, Shlomo A. Koyfman, David J. Adelstein, Brian B. Burkey, Jeppe Friborg, Claus Andrup Kristensen, Anita Gothelf, Frank Hoebers, Bernd Kremer, Ernst‐Jan M. Speel, Daniel W. Bowles, David Raben, Sana D. Karam, Eugene Yu, Wei Xu - The Lancet Oncology 2016 cited by 741

  8. Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial

    Authors: Luis Paz‐Ares, Alexander I. Spira, David Raben, David Planchard, Byoung Chul Cho, Mustafa Özgüroğlu, Davey B. Daniel, Augusto Villegas, David Vicente, Rina Hui, S. Murakami, David R. Spigel, Suresh Senan, Corey J. Langer, Bradford A. Perez, A-M. Boothman, Helen Broadhurst, Catherine Wadsworth, P. Dennis, Scott Antonia, Corinne Faivre‐Finn - Annals of Oncology 2020 cited by 224

  9. Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non–Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors

    Authors: Diana Merino Vega, Katherine K. Nishimura, Névine Zariffa, Jeffrey C. Thompson, Antje Hoering, Vanessa Cilento, Adam Rosenthal, Valsamo Anagnostou, Jonathan Baden, Julia A. Beaver, Aadel A. Chaudhuri, Darya Chudova, Alexander D. Fine, Joseph Fiore, Rachel Hodge, Darren Hodgson, Nathan Hunkapiller, Daniel M. Klass, Julie Kobie, Carol E. Peña, Gene Pennello, Neil Peterman, Reena Philip, Katie Quinn, David Raben, Gary L. Rosner, Mark Sausen, Ayse Tezcan, Qi Xia, Jing Yi, Amanda Young, Mark Stewart, Erica L. Carpenter, Charu Aggarwal, Jeff Allen - JCO Precision Oncology 2022 cited by 75

  10. STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer

    Authors: Ayman Oweida, Laurel B. Darragh, Andy V. Phan, David C. Binder, Shilpa Bhatia, Adam C. Mueller, Benjamin Van Court, Dallin Milner, David Raben, Richard Woessner, Lynn E. Heasley, Raphael A. Nemenoff, Eric T. Clambey, Sana D. Karam - JNCI Journal of the National Cancer Institute 2019 cited by 153

  11. Prostate Cancer, Version 1.2016

    Authors: James L. Mohler, Andrew J. Armstrong, Robert R. Bahnson, Anthony V. D’Amico, Brian J. Davis, James A. Eastham, Charles A. Enke, Thomas A. Farrington, Celestia S. Higano, Eric M. Horwitz, Michael E. Hurwitz, Christopher J. Kane, Mark H. Kawachi, Michael Kuettel, Richard J. Lee, Joshua J. Meeks, David F. Penson, Elizabeth R. Plimack, Julio M. Pow‐Sang, David Raben, Sylvia Richey, Mack Roach, Stan Rosenfeld, Edward M. Schaeffer, Ted A. Skolarus, Eric J. Small, Guru Sonpavde, Sandy Srinivas, Seth A. Strope, Jonathan D. Tward, Dorothy A. Shead, Deborah A. Freedman-Cass - Journal of the National Comprehensive Cancer Network 2016 cited by 655

  12. The Integration of Radiotherapy with Immunotherapy for the Treatment of Non–Small Cell Lung Cancer

    Authors: Eric C. Ko, David Raben, Silvia C. Formenti - Clinical Cancer Research 2018 cited by 300

  13. Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma

    Authors: Ayman Oweida, Shelby Lennon, Dylan Calame, Sean P. Korpela, Shilpa Bhatia, Jaspreet Sharma, Caleb Graham, David C. Binder, Natalie J. Serkova, David Raben, Lynn E. Heasley, Eric T. Clambey, Raphael A. Nemenoff, Sana D. Karam - OncoImmunology 2017 cited by 126

  14. p16 Protein Expression and Human Papillomavirus Status As Prognostic Biomarkers of Nonoropharyngeal Head and Neck Squamous Cell Carcinoma

    Authors: Christine H. Chung, Qiang Zhang, Christina S. Kong, Jonathan Harris, Elana J. Fertig, Paul M. Harari, Dian Wang, Kevin P. Redmond, George Shenouda, Andy Trotti, David Raben, Maura L. Gillison, Richard C. Jordan, Quynh‐Thu Le - Journal of Clinical Oncology 2014 cited by 377

  15. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer

    Authors: Sana D. Karam, Krishna Reddy, Patrick J. Blatchford, Tim Waxweiler, Alicia M. DeLouize, Ayman Oweida, Hilary Somerset, Carrie B. Marshall, Christian D. Young, Kurtis D. Davies, Madeleine Kane, Aik Choon Tan, Xiaojing Wang, Antonio Jimeno, Dara L. Aisner, Daniel W. Bowles, David Raben - Clinical Cancer Research 2018 cited by 93

  16. Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

    Authors: Solange Peters, Urania Dafni, Michael Boyer, Dirk De Ruysscher, Corinne Faivre‐Finn, Enriqueta Felip, Pilar Garrido, Nicolas Girard, Matthias Gückenberger, John B.A.G. Haanen, C. Le Péchoux, F. Mornex, Mahmut Özsahin, Luis Paz‐Ares, David Planchard, David Raben, Suresh S. Ramalingam, Martin Reck, Egbert F. Smit, R. Stahel, Albrecht Stenzinger, Charles Swanton, S. Vallone, Marina Chiara Garassino - Annals of Oncology 2019 cited by 76

  17. Patterns of Disease Progression with Durvalumab in Stage III Non-small Cell Lung Cancer (PACIFIC)

    Authors: David Raben, Andreas Rimner, Suresh Senan, Helen Broadhurst, Theodore C. Pellas, Phillip A. Dennis, Corinne Faivre‐Finn - International Journal of Radiation Oncology*Biology*Physics 2019 cited by 66

  18. Establishing quality indicators for neck dissection: Correlating the number of lymph nodes with oncologic outcomes (NRG Oncology RTOG 9501 and RTOG 0234)

    Authors: Vasu Divi, Jonathan Harris, Paul M. Harari, Jay S. Cooper, Jonathan B. McHugh, Diana Bell, Erich M. Sturgis, Anthony J. Cmelak, Mohan Suntharalingam, David Raben, Harold Kim, Sharon A. Spencer, George E. Laramore, Andy Trotti, Robert L. Foote, Christopher J. Schultz, Wade L. Thorstad, Qiang Zhang, Quynh‐Thu Le, F. Christopher Holsinger - Cancer 2016 cited by 104

  19. A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma

    Authors: Thomas J. Galloway, Lori J. Wirth, A. D. Colevas, Jill Gilbert, Julie E. Bauman, Nabil F. Saba, David Raben, Ranee Mehra, Anna Walaszczyk, Ruzanna Atoyan, Jing Wang, Barbara Burtness, Antonio Jimeno - Clinical Cancer Research 2015 cited by 99

  20. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins

    Authors: Stephen B. Keysar, David P. Astling, Ryan T. Anderson, Brian W. Vogler, Daniel W. Bowles, J. Jason Morton, Jeramiah J. Paylor, Magdalena J. Glogowska, Phuong N. Le, Justin R. Eagles-Soukup, Severine Kako, Sarah M. Takimoto, Daniel Sehrt, Adrian Umpierrez, Morgan A. Pittman, Sarah M. Macfadden, Ryan M. Helber, Scott Peterson, Diana F. Hausman, Sherif Said, Ted H. Leem, Julie Goddard, John J. Arcaroli, Wells A. Messersmith, William A. Robinson, Fred R. Hirsch, Marileila Varella‐Garcia, David Raben, Xiao‐Jing Wang, John I. Song, Aik Choon Tan, Antonio Jimeno - Molecular Oncology 2013 cited by 164

  21. Association of Adjuvant Chemoradiotherapy vs Radiotherapy Alone With Survival in Patients With Resected Major Salivary Gland Carcinoma

    Authors: Arya Amini, Timothy V. Waxweiler, Jeffrey V. Brower, Bernard L. Jones, Jessica D. McDermott, David Raben, Debashis Ghosh, Daniel W. Bowles, Sana D. Karam - JAMA Otolaryngology–Head & Neck Surgery 2016 cited by 132

  22. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies

    Authors: Reshmi S. Nair, Veena Somasundaram, Anshu Kuriakose, Shiv Ram Krishn, David Raben, Rachel Salazar, Pradip Nair - Frontiers in Immunology 2025 cited by 58

  23. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma

    Authors: Alexander A. Strait, Rachel A. Woolaver, Spencer C. Hall, Christian D. Young, Sana D. Karam, Antonio Jimeno, Yan Lan, David Raben, Jing Wang, Xiao‐Jing Wang - Communications Biology 2021 cited by 21

  24. A comprehensive comparative analysis of treatment modalities for sinonasal malignancies

    Authors: Tyler P. Robin, Bernard L. Jones, Oren Gordon, Andy V. Phan, Diana Abbott, Jessica D. McDermott, Julie Goddard, David Raben, Ryan M. Lanning, Sana D. Karam - Cancer 2017 cited by 172